WBURGenzyme Spurns Buyout Offer From French Pharma

Listen Now

BOSTON — The biggest bio-tech company in Massachusetts has spurned a proposal from one of the world’s biggest pharmaceutical firms.

Cambridge-based Genzyme Co. said “no” Monday to a buyout offer from Sanofi-Aventis, which is headquartered in France.

The two companies have been in talks since July, but Geoffrey Porges says there have been signs of a “courtship” over the past year. Porges is senior bio-tech analyst with Sanford C. Bernstein and Co. in New York.  Porges spoke with Morning Edition to discuss the negotiations.

WBUR Topics · Boston · Health · Science & Technology
Please follow our community rules when engaging in comment discussion on wbur.org.
  • ms

    What the hell does “spurned” mean?
    I can figure it out in the context of the sentenance, but who uses such an irrelevent word?There’s a dozen other words that would fit better.
    Get a clue dude!

  • FXB

    @ms

    Are you serious?

More stories in 'Science & Technology'
 
UNDERWRITING
Most Popular
SUPPORT
Arts, Music and Theater
SUPPORT
This site is best viewed with: Firefox | Internet Explorer 9 | Chrome | Safari
Reporting Copyright Infringement